Contineum Therapeutics, Inc. (CTNM)
NASDAQ · Healthcare
Contineum Therapeutics, Inc. Revenue 2023–2024
Contineum Therapeutics, Inc. annual/quarterly revenue history and growth rate from 2023 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Contineum Therapeutics, Inc. revenue for the quarter ending September 30, 2024 was 0.
- Contineum Therapeutics, Inc. revenue for the twelve months ending September 30, 2024 was 50.0 M.
- Contineum Therapeutics, Inc. annual revenue for 2024 was 0, a 100.00% decrease from 2023.
- Contineum Therapeutics, Inc. annual revenue for 2023 was 50.0 M.
Revenue
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Contineum Therapeutics, Inc. (CTNM) — Frequently Asked Questions
Contineum Therapeutics, Inc. (CTNM) is a publicly traded US company. It has a market capitalization of $230M. Explore CTNM's stock price, financial statements, earnings history, margins and key ratios below.
What is Contineum Therapeutics, Inc.'s market cap?
Contineum Therapeutics, Inc. (CTNM) has a market capitalization of $230M.
What is the CTNM stock price?
CTNM trades at $11.86 (+4.96% on the day).
Is CTNM profitable?
In fiscal 2024, Contineum Therapeutics, Inc. reported net income of -$42M.